Latest Breaking News On - புற்றுநோயியல் வணிக அலகு - Page 1 : comparemela.com

  of extensive-stage small cell lung cancer   Only PD-1/PD-L1 immunotherapy to demonstrate both a significant survival benefit and improved response rate in combination with a choice of chemotherapies   AstraZeneca s Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin).   The approval by China s National Medical Products Administration was based on positive results from the CASPIAN Phase III trial. The trial showed that Imfinzi plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus chemotherapy alone. In addition, results from the China cohort of patients were consistent with the global results.

United kingdomUnited statesDave fredricksonAstrazeneca imfinziDaiichi sankyoAdrian kempNational cancer instituteWorld health organizationLung ambition allianceCompany on twitter astrazenecaLungevity foundationChina national medical products administrationInvestor relations teamInternational agency for research on cancerNational medical products administrationExecutive vice president